ORCHID PHARMABreakout happend in this stock with rising 200dma and RS indicator is also showing strength.
Keep your risk and reward ratios according to your own preferance.
This is for educational purpose, do your own research before investing.
ORCHPHARMA trade ideas
ORCHPHARMA Giving a Strong BreakOutOrchid Pharma Ltd. engages in the development, manufacture, and marketing of diverse bulk actives, formulations, and nutraceuticals. Its products include cardiovascular, anti-diabetic, neuropsychiatry, nutritional supplements, cephalosporins-orals, cephalosporins-injectables, veterinary products, and non-antibiotics. The company was founded by Kailasam Raghavendra Rao on July 1, 1992, and is headquartered in Chennai, India.
Can Keep
Stop_Loss - 1,400
Target_1 - 1,625
Target_2 - Trail With 20-EMA
ORCHPHARMA - Bullish SetupStock name - Orchid Pharma Limited.
Weekly chart setup
Chart is self explanatory. Levels of breakout, possible up-moves (where stock may find resistances) and support (close below which, setup will be invalidated) are clearly defined.
Master Score - C
Disclaimer: This is for demonstration and educational purpose only. this is not buying and selling recommendations. I am not SEBI registered. please consult your financial advisor before taking any trade.
ORCHID PharmaOrchid pharma: Breakout above 1350, which was its previous high as well.
If we see a breakout with volumes then a fresh spike may come.
One can take at the re test level as well .
Disclaimer: only for education purposes, no buy or sell recommendation. we are not sebi registered. always discuss first with your financial advisors
orchpharma1. Anything can happen.
2. You don't need to know what is going to happen next in order to make money.
3. There is a random distribution between wins and losses for any given set of variables that define an edge. No other thoughts
4. An edge is nothing more than an indication of a higher probability of one thing happening over another.
5. Every moment in the market is unique.
ORCHID
** Adds ORCD is set for strong growth over the next three years as new management continues to execute the turnaround strategy well
** Co leveraging core strengths in key active pharma ingredients (APIs)-like anti-microbials such as Cephalosporin,
** Estimates 35%+ compound annual growth rate (CAGR) in earnings before interest, taxes, depreciation and amortisation (EBITDA) over fiscal 2023-2026
Orchid Pharma - New ManagementOrchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs
Product Portfolio
The Co has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardio vascular segment (CVS), nutraceuticals and other oral and sterile products. Its Product portfolio constitute of API - Cephalosporins - Orals, Cephalosporins - Injectables, Veterinary Products & Non-Antibiotics.
Geographical Split
India: 12 % in FY21 vs 9% in FY20
Rest of World: 88 % in FY21 vs 91% in FY20
Acquisition by Dhanuka Laboratories Ltd (DLL)
The Co was acquired by Dhanuka Laboratories Ltd under Corporate Insolvency Resolution Process and the plan was implemented in March 2020. It allotted 3.99 Crore equity shares to Dhanuka Laboratories Ltd for cash it also allotted 10,000 equity shares pursuant to the Scheme of Amalgamation to DLL.
Debt Settlement
The Co allocated 4,08,164 Equity Shares to the eligible Secured Financial Creditors for the conversion and settlement of part of their Debt.
General Notes
1. There is lot of buzz and activites in Orchid Pharma recently with promoters releasing pledge of shares which is positive sign
2. Co has reduced debt significantly because of debt settlement with bankers with haircut
3. EPS is subdued in negative but on consolidated basis they are looking good
4. Debt has been reduced to 50% from YOY and Reserves have turned positive from last 3 years
5. Other indicators such as debtors inventory ageing and payable days dont have much negativity. QOQ are running at the same pace.
6.There has lot of concalls and presentations by the co in recent times and with new management in hope to turnaround is looking to be trustable
7.This worth a buy at 330 for long term holding
